PTGX 株価分析 — Protagonist Therapeutics Inc (Healthcare >> Biotechnology)
PTGX に関するよくある質問
PTGXのPER(株価収益率)は?
Protagonist Therapeutics Inc(PTGX)は現在PER 2,356.89倍で取引されています。
PTGXのROE(自己資本利益率)は?
Protagonist Therapeutics IncのROEは-17.50%です。
PTGXの配当利回りは?
Protagonist Therapeutics Incの配当利回りは0.00%です。
PTGXの品質スコア(Quality Score)は?
当社のAIはPTGXの総合財務品質を100点中15点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
PTGXは今が買い時ですか?
当社AIのタイミングスコアは100点中87点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
PTGXはどのセクターに属しますか?
Protagonist Therapeutics IncはHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
PTGX AI Analysis Summary
Our AI summary for PTGX: Protagonist Therapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 2,356.89, ROE of -17.50%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 136.64
Price
-2.00
(-1.44%)
Day Change
|
|
|---|
PTGX, ファンダメンタルスコアはnot good ( ファンダメンタル = 15) but テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 136.64 |
| PBV / Sector |
13.60 / 5.20
|
| Earning Per Share | -1.76 |
| PE / Sector |
2,356.89 / 19.97
|
| PEG or PE/Growth / Sector |
-11.84 / 1.22
|
| Average 1M Daily Value |
84.94 M
|
| Average 1W Daily Value |
62.31 M
|
| Timing Factors |
|
71% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:21 |
| Symbol | PTGX |
| Name | PROTAGONIST THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 64.31 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 8,916.13 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 7707 Gateway Boulevard, Newark, CA, United States, 94560
Phone: 510 474 0170
Website: https://www.protagonist-inc.com
Employees: 131
Sector: Healthcare >> Biotechnology
Description: Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google